Download PDF
Z Gastroenterol 2003; 41(10): 1039-1045
DOI: 10.1055/s-2003-42922
Mitteilungen
© Karl Demeter Verlag im Georg Thieme Verlag Stuttgart · New York

ASCO Update 2003 - Highlights vom 39. Kongress der American Society of Clinical Oncology/ASCO 2003

ASCO Update 2003 - Highlights of the 39th Meeting of the American Society of Clinical Oncology/ASCO 2003T. Eberl1 , U. Graeven2 , M. Heike3 , T. Höhler4 , M. P. Lutz5 , H. Messmann1 , T. Seufferlein6 , für die Arbeitsgemeinschaft Gastroenterologische Onkologie der DGVS
  • 1Medizinische Klinik III, Klinikum Augsburg
  • 2Medizinische Universitätsklinik, Knappschaftskrankenhaus, Ruhr-Universität Bochum
  • 3Medizinische Klinik Mitte, Klinikum Dortmund
  • 4Medizinische Klinik und Poliklinik, Johannes-Gutenberg-Universität Mainz
  • 5Medizinische Klinik, Caritasklinik St. Theresia, Saarbrücken
  • 6Abt. Innere Medizin I, Universitätsklinikum Ulm
Further Information

Publication History

Publication Date:
16 October 2003 (online)

Also available at
    Permissions and Reprints

Wir möchten Ihnen auch dieses Jahr wieder die „Highlights” des diesjährigen ASCO-Meetings aus dem Bereich der gastrointestinalen Tumoren vorstellen. Dieser Bericht erhebt keinen Anspruch auf Vollständigkeit. Wir haben uns bemüht, solche Studien darzustellen, die in nächster Zeit unsere tägliche klinische Arbeit beeinflussen werden und die noch nicht anlässlich anderer Kongresse vorgestellt worden sind. Beim Nachlesen des einen oder anderen Abstracts wird möglicherweise auffallen, dass die unten angegebenen Zahlen sich manchmal etwas von den Zahlen im Abstract unterscheiden. Es ist eine Besonderheit dieses Kongresses, dass viele Studien auch nach Einreichung des Abstracts weiter ausgewertet werden und dann die aktuellsten Daten auf dem Meeting präsentiert werden. Diese Daten haben wir für unsere Übersicht verwendet.

Literatur

  • 1 Abid L, Oukkal M, Berkane S. et al . Phase II trial with the gemcitabine and cisplatin combination in the treatment of locally advanced and metastatic gall bladder carcinoma.  Proc ASCO. 2003;  22 1302
    PubMedGoogle Scholar
  • 2 Ajani J A, Van Cutsem E, Moiseyenko V. et al . Docetaxel (D), cisplatin, 5-fluorouracil ccompared to cisplatin (C) and 5-fluorouracil (F) for chemotherapy-naïve patients with metastatic or locally recurrent, unresectable gastric carcinoma (MGC): Interim results of a randomized phase III trial.  Proc ASCO. 2003;  22 999
    PubMedGoogle Scholar
  • 3 Allum D, Cunningham D, Weeden S. Perioperative chemotherapy in operable gastric and lower oesophageal cancer: A randomised, controlled trial (the MAGIC trial, ISRCTN 93 793 971).  Proc ASCO. 2003;  22 998
    PubMedGoogle Scholar
  • 4 Ardalan B, Livingstone A, Fancheschi D. et al . Neoadjuvant (NAD), adjuvant (AD) treatment without radiation in patients with advanced operable adenocarcinoma of esophagus.  Proc ASCO. 2003;  22 1309
    PubMedGoogle Scholar
  • 5 Armanios M Y, Xu R, Forastiere D G. et al . Phase II adjuvant chemotherapy for resected adenocarcinoma of the esophagus, gastroesophageal (GE) junction and cardia (E8296): A trial of the Eastern Cooperative Oncology Group.  Proc ASCO. 2003;  22 1190
    PubMedGoogle Scholar
  • 6 Bedenne P M, Michel O, Triboulet J P. et al . Randomized phase III trial in locally advanced esophageal cancer: radiochemotherapy followed by surgery versus radiochemotherapy alone (FFCD 9102).  Proc ASCO. 2002;  21 519
    PubMedGoogle Scholar
  • 7 Bonnetain F, Bedenne P, Michel P. et al . Definitive results of a comparative longitudinal quality of life study using the Spitzer index in the randomized multicentric phase III trial FFCD 9102 (surgery vs radiochemotherapy in patients with locally advanced esophageal cancer.  Proc ASCO. 2003;  22 1001
    PubMedGoogle Scholar
  • 8 Bouche O, Raoul J L, Giovanini M. et al . Randomized phase II trial of LV5FU2, LV5FU2-cisplatinum or LV5FU2-irinitecan in patients with metastastic gastric or cardial adenocarcinoma (MGA): Final results of study FFCD9803.  Proc ASCO. 2003;  22 1002
    PubMedGoogle Scholar
  • 9 Burris H A, Moore M J, Andersen J. et al . Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial.  J Clin Oncol. 1997;  15 2403-2413
    CrossrefPubMedGoogle Scholar
  • 10 Cebon J S, Findlay M, Hargreaves C. et al . Somatostatin receptor expression and clinical effects of octreotide LAR in patients with advanced hepatocellular carcinoma.  Proc ASCO. 2003;  22 1163
    PubMedGoogle Scholar
  • 11 Cunningham D, Humblet Y, Siena D. et al . Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC).  Proc ASCO. 2003;  22 1012
    PubMedGoogle Scholar
  • 12 de Gramont A, Banzi M, Navarro M. et al . Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial.  Proc ASCO. 2003;  22 1015
    PubMedGoogle Scholar
  • 13 Frustaci S, Bearz A, Basso B. et al . Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcinoma (HCC).  Proc ASCO. 2003;  22 335
    PubMedGoogle Scholar
  • 14 Fujii M, Kosaki G, Tsuchiya S for the Gastric Cancer Chemotherapy Group of Japan. et al . Randomized trial of preoperative adjuvant chemotherapy using oral 5-FU in operable gastric cancer [Abstract].  Proc ASCO. 1999;  18 272
    PubMedGoogle Scholar
  • 15 Fung M C, Ishiguro H, Takayama S. et al . Survival Benefit of Chemotherapy Treatment in Advanced Pancreatic Cancer: A Meta-analysis.  Proc ASCO. 2003;  22 1155
    PubMedGoogle Scholar
  • 16 Gibson M K, Abraham S, Wu T T. et al . Epidermal growth factor receptor, p53 mutation and pathologi c response pedict survival in patients with locally advanced esophageal cancer treated with pre-operative chemotherapy.  Proc ASCO. 2003;  22 1030
    PubMedGoogle Scholar
  • 17 Hamburg S, Miller W, Garcia-Vargas J. et al . Survival benefit of nolatrexed in advanced hepatocellular carcinoma (aHCC).  Proc ASCO. 2003;  22 288
    PubMedGoogle Scholar
  • 18 Hawkins R, Cunningham D, Soerbye H. et al . Randomized phase II trial of docetaxel plus irinotecan versus docetaxel plus 5-fluorouracil (5FU) in patients with untreated advanced gastric adenocarcinoma (AGAC).  Proc ASCO. 2003;  22 257
    PubMedGoogle Scholar
  • 19 Hecht J R, Ajani A, Michaeli D. et al . A multicenter phase II study of cisplatin (CDDP) and 5-fluorouracil (5-FU) in combination with G17DT immunogen in patients with locally recurrent or metastatic adenocarcinoma of the stomach or gastroesophageal junction previously untreated for advanced disease.  Proc ASCO. 2003;  22 1035
    PubMedGoogle Scholar
  • 20 Hegewisch-Becker S, Corovic A, Jaeger E. et al . Whole body hyperthermia (WBH, 41.8 C) combined with carboplatin and etoposide in advanced biliary tract cancer.  Proc ASCO. 2003;  22 311
    PubMedGoogle Scholar
  • 21 Heinemann V, Quietzsch D, Gieseler F. et al . A phase III trial comparing gemcitabine plus cisplatin vs. gemcitabine alone in advanced pancreatic carcinoma.  Proc ASCO. 2003;  22 1003
    PubMedGoogle Scholar
  • 22 Hsu C, Shen Y C, Yang C H. et al . Phase II study of weekly gemcitabine plus 24-hour infusion of high-dose 5-fluorouracil/leucovorin for locally advanced or metastatic carcinoma of the biliary tract.  Proc ASCO. 2003;  22 1322
    PubMedGoogle Scholar
  • 23 Hurwitz H, Fehrenbacher L, Cartwright T. et al . Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC.  Proc ASCO. 2003;  22 3646
    PubMedGoogle Scholar
  • 24 Ishii H, Furuse J, Nagase M. et al . Relief of jaundice by external beam radiotherapy and intraluminal brachytherapy in patients with extrahepatic cholangiocarcinoma: Results without stenting.  Proc ASCO. 2003;  22 1219
    PubMedGoogle Scholar
  • 25 Ishikura S, Ohtsu A, Shiaro K. et al . A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group study (JCOG9908-DI).  Proc ASCO. 2003;  22 1106
    PubMedGoogle Scholar
  • 26 Izzo F, Marra P, Beneduce G. et al . Phase I/II testing of pegylated arginine deiminase in subjects with hepatocellular carcinoma.  Proc ASCO. 2003;  22 1474
    PubMedGoogle Scholar
  • 27 Jacobson S D, Alberts S R, Mahoney M R. et al . Phase II trial of gemcitabine (Gem), 5-fluorouracil (5FU), and leucovorin (LV) in patients with unresectable or metastatic biliary (Bili) and gallbladder (GB) carcinoma: A North Central Cancer Treatment Group (NCCTG) study.  Proc ASCO. 2003;  22 1102
    PubMedGoogle Scholar
  • 28 Kang Y K, Choi D W, Im Y H. et al . A phase III randomized comparison of neoadjuvant chemotherapy followed by surgery versus surgery for locally advanced stomach cancer.  Proc ASCO. 1996;  15 215
    PubMedGoogle Scholar
  • 29 Kato H, Udagawa H, Togo A. et al . A phase II trial of chemo-radiotherapy in patients with stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9780).  Proc ASCO. 2003;  22 1147
    PubMedGoogle Scholar
  • 30 Kindler H L, Ansari R, Lester E. Bevacizumab (B) plus gemcitabine (G) in patients (pts) with advanced pancreatic cancer (PC).  Proc ASCO. 2003;  22 1037
    PubMedGoogle Scholar
  • 31 Köhne C H, Van Cutsem E, Wils J A. et al . Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40 986.  Proc ASCO. 2003;  22 1018
    PubMedGoogle Scholar
  • 32 Lee J L, Kim S B, Jung H Y. et al . A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery (CRT-S) versus surgery (S) alone for stage II, III respectable esophageal squamous cell carcinoma (SCC): An interim analysis.  Proc ASCO. 2003;  22 1043
    PubMedGoogle Scholar
  • 33 Leung T WT, Mo F, Leow C K. et al . Multicenter validation of the Chinese University Prognostic Index (CUPI) for hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1040
    PubMedGoogle Scholar
  • 34 Louvet C, Labianca R, Hammel P. et al . Gemcitabine versus GEMOX (gemcitabine + oxalipaltin) in non resectable pancreatic adenocarcinom: Interim results of the GERCOR/GISCAD Intergroup Phase III.  Proc ASCO. 2003;  22 1004
    PubMedGoogle Scholar
  • 35 Mal F, Perniceni H, Levard E. et al . Predictive factors of post operative early redux of oesophageal or cardial adenocarcinoma: A retrospective study in 100 patients.  Proc ASCO. 2003;  22 1350
    PubMedGoogle Scholar
  • 36 Mantravadi R VP, Fineberg N, Ansari A. et al . A phase Ii study of cisplatin, 5-fluorouracil (5-FU), radiation 8RT) and celecoxib in patients with resectable esophageal cancer 8EC): Preliminary results from the Hoosier Oncology Group (HOG).  Proc ASCO. 2003;  22 1168
    PubMedGoogle Scholar
  • 37 Moehler M H, Siebler J, Hoehler T. et al . Safety and efficacy of CPT11/FA/5-FU (ILF) versus ELF in previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction.  Proc ASCO. 2003;  22 1034
    PubMedGoogle Scholar
  • 38 Muro K, Ando N, Nishimaki T. A phase II study of nedaplatin and 5-fluorouracil in metastatic squamous cell carcinoma of the esophagus: The Japan Clinical Oncology Group (JCOG) trial (JCOG 9905).  Proc ASCO. 2003;  22 1112
    PubMedGoogle Scholar
  • 39 Nehls O, Oettle H, Hartmann J T. et al . Oxaliplatin plus capecitabine in advanced biliary system adenocarcinomas: A multicenter phase II trial.  Proc ASCO. 2003;  22 1126
    PubMedGoogle Scholar
  • 40 Rizk N, Akhurst R, Downey R J. et al . FDG PET scanning predicts tumor stage and survival in esophageal adenocarcinoma.  Proc ASCO. 2003;  22 1085
    PubMedGoogle Scholar
  • 41 Reyes-Vidal J, Gallardo J, Yanez E. et al . Gemcitabine (G) and cisplatin (C) in the treatment of patients (pts) with unresectable or metastatic gallbladder cancer: Results of the phase II GOCCHI study.  Proc ASCO. 2003;  22 1095
    PubMedGoogle Scholar
  • 42 Rocha-Lima C MS, Rotche R, Jeffery M. et al . A randomized phase 3 study comparing theefficacy and safety of gemcitabine (GEM) and irinotecan (I), to GEM alone in patients with locally advanced or metastatic pancreatic cancer who have not received prior systemic therapy.  Proc ASCO. 2003;  22 1005
    PubMedGoogle Scholar
  • 43 Ross P, Nicolson M, Cunningham D. et al . Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer.  J Clin Oncol. 2002;  20 1996-2004
    CrossrefPubMedGoogle Scholar
  • 44 Scheithauer W, Schuell B, Dworan N. et al . Mitomycin C in combination with capecitabine or biweekly high dose gemcitabine in patients with advanced biliary tract cancer (ABC).  Proc ASCO. 2003;  22 1059
    PubMedGoogle Scholar
  • 45 Songun I, Keizer H J, Hermans J. et al . Chemotherapy for operable gastric cancer: results from the Dutch randomized FAMTX trial. The Dutch Gastric Cancer Group (DGCG).  Eur J Cancer. 1999;  35 558-562
    CrossrefPubMedGoogle Scholar
  • 46 Stahl M, Wilke H, Walz M K. et al . Randomized phase III trial in locally advanced squamous cell carcinoma (SCC) of the esophagus: Chemoradiation with and without surgery.  Proc ASCO. 2003;  22 1001
    PubMedGoogle Scholar
  • 47 Stuart K, Eder J P, Proper J. et al . Phase II trial of irofulven in patients with unresectable hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1107
    PubMedGoogle Scholar
  • 48 Sumpter K A, Harper-Wynne C, Cunningham D. et al . Randomised multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation.  Proc ASCO. 2003;  22 1031
    PubMedGoogle Scholar
  • 49 Sun Y, Li H, Lin Z. et al . Phase I and pharmacokinetic study of nemorubicin hydrochloride (methoxymorpholino doxorubicin; PNU-152 243) administered with iodinated oil via hepatic artery (IHA) to patients (pt) with unresectable hepatocellular carcinoma (HCC).  Proc ASCO. 2003;  22 1448
    PubMedGoogle Scholar
  • 50 Tempero M, Plunkett W, Ruiz Van Haperen V. et al . Randomized phase II trial of dose intense gemcitabine by standard infusion vs fixed dose rate in metastatic pancreatic adenocarcinoma.  Proc ASCO. 1999;  18 1048
    PubMedGoogle Scholar
  • 51 Thongprasert S, Napapan S, Charoentum C. et al . Phase II study of gemcitabine plus cisplatin in biliary tract cancer.  Proc ASCO. 2003;  22 1221
    PubMedGoogle Scholar
  • 52 Treiber G, Heinrich U, Fostitsch P. et al . Palliative treatment of hepatocellular carcinoma (HCC) using octreotide, rofecoxib, or both.  Proc ASCO. 2003;  22 1281
    PubMedGoogle Scholar
  • 53 Tsuji A, Morita S, Horimi T. et al . A phase II study of 5-FU (CVI) and low-dose consecutive CDDP (LFP) therapy in advanced bile duct carcinoma.  Proc ASCO. 2003;  22 1484
    PubMedGoogle Scholar
  • 54 Webb A, Cunningham D, Scarffe J H. et al . Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.  J Clin Oncol. 1997;  15 261-267
    PubMedGoogle Scholar
  • 55 Yang T S, Chang W C, Lin Y C. et al . A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma.  Proc ASCO. 2003;  22 1351
    PubMedGoogle Scholar

PD Dr. Thomas Seufferlein

Abt. für Innere Medizin der Medizinischen Universitätsklinik Ulm

Robert-Koch-Straße 8

89081 Ulm